GlassScriptPhysician profile
Mark W Fender
NPI 1447205539
$1,155.47
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $157 · 2021: $51.19 · 2022: $81.36 · 2023: $277 · 2024: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.46 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $163.69 | 2020-2024 | Entyvio |
| Janssen Biotech, INC. | $148.07 | 2023-2024 | Stelara, Simponi Aria, Simponi |
| Heron Therapeutics, INC. | $108.61 | 2023-2024 | Aponvie, Zynrelef |
| Ucb, INC. | $96.50 | 2019 | |
| Shionogi INC | $78.83 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $72.20 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $64.30 | 2020-2022 | |
| Abbvie INC. | $62.55 | 2019-2024 | |
| Pacira Pharmaceuticals Incorporated | $35.14 | 2021 | |
| Mallinckrodt Enterprises LLC | $21.02 | 2019 | |
| Boston Scientific Corporation | $16.51 | 2022 | |
| Braintree Laboratories, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.